CSRxP Statement on Novartis’ $475,000 Price Tag for Kymriah

08-30-2017 Blog PostsPress Release

“While we are very excited about the potential for CAR-T therapies to save lives, Novartis’ pricing decision disappointingly pushes an unsustainable trend even closer to the breaking point.”

CSRxP Calls for Action on CREATES Act

07-27-2017 Blog PostsPress Release

CSRxP Calls for Action on CREATES Act The Campaign for Sustainable Rx Pricing released this statement from spokesman Will Holley on today’s House Judiciary Subcommittee on Regulatory Reform, Commercial and Antitrust Law hearing on Antitrust Concerns and the FDA Approval Process:  “Out-of-control prescription drug prices are an epidemic that harm all Americans. They affect not […]

Avik Roy Unveils “The Competition Prescription”

05-16-2017 Blog PostsPress Release

Read “The Competition Prescription,” a new white paper by Avik Roy, President of Foundation for Research on Equal Opportunity on how federal policy has artificially driven up the cost of prescription drugs, and market-based reforms to bring prices down.

CSRxP Applauds Introduction of the CREATES Act

04-27-2017 Blog PostsPress Release

“Big Pharma’s longstanding pattern of utilizing the REMS process to forestall generic and biosimilar medications from reaching patients is an anticompetitive and cynical abuse of an important tool for patient safety.”

Campaign Continues to Grow with Additional Physician Voices

11-3-2016 Blog PostsPress Release

“The addition of the well-respected Society of General Internal Medicine is crucial as CSRxP continues to build a broad partnership of leaders from every corner of healthcare that are dedicated to fixing the broken prescription drug market,” said CSRxP Executive Director John Rother.

Improving the Prescription Drug Market through Transparency, Competition, and Value

08-3-2016 Blog PostsMediaPress Release

“Patients with chronic conditions, such as Hepatitis C, benefit immensely when breakthrough, life-changing drugs provide a cure where none existed before. But when states are driven to create access limitations to that same drug for their Medicaid populations, we have to acknowledge something is not quite right here.”

CSRxP Statement on Launch of AstraZeneca’s Crestor

07-21-2016 Blog PostsPress Release

“We are glad to see that the court rejected AstraZeneca’s effort to abuse the Orphan Drug Act and restrict generic competitors to Crestor,” said John Rother. “Additional competition in the prescription drug market—including generic options—is crucial to lowering prescription drug prices and providing patients with more affordable choices.”

Campaign Discusses Market-Based Solutions to Drug Pricing on Capitol Hill

07-14-2016 Blog PostsMediaPress Release

Members of the Campaign for Sustainable Rx Pricing (CSRxP) gathered on Capitol Hill to discuss market-based policy solutions to curb rising drug prices.

Campaign Launches Nationwide Effort to Highlight Voter Concerns Over Rising Prescription Drug Prices

07-11-2016 Blog PostsPress Release

“Voters across the country are calling for action by their elected officials to make sure patients and families don’t have to choose between filling a prescription and putting food on the table,” said CSRxP Executive Director John Rother. “The trend of rising drug prices needs to be addressed, and we expect voters will take that message – and a call for solutions – to candidates at all levels this fall.”

Drug Companies Protecting Their Monopoly To Keep Prices High

07-11-2016 Blog PostsMediaPress Release

Our new board game illustrates how pharmaceutical companies have a monopoly on the current pricing system and the different ways they keep prices high.

Sign-up for updates

  • This field is for validation purposes and should be left unchanged.